<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04154722</url>
  </required_header>
  <id_info>
    <org_study_id>0980419HRPED</org_study_id>
    <nct_id>NCT04154722</nct_id>
  </id_info>
  <brief_title>Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children</brief_title>
  <acronym>[XDRTYPHOID]</acronym>
  <official_title>Treatment of 21st Century Typhoid Fever in Children;Open Label Mono vs Combination Drug Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziauddin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziauddin University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether XDR Typhoid fever in children can be effectively treated with
      monotherapy (meropenum alone), or a combination (meropenum and azithromycin).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Complicated XDR Enteric fever is a very serious systemic disease, caused by an extremely
      resistant mutant strain of Salmonella Typhi ( the H58 S. Typhi superbug,) that as the name
      suggests is resistant to not only the first but also the second tier drugs conventionally
      used for treatment of the same. And as such, warrants immediate antibiotic therapy, but in
      view of the extended antimicrobial resistance the treatment options are limited to only two
      effective drugs viz Carbepenem and Azithromycin, as per culture sensitivity.

      So far, in the absence of universal standardized treatment protocols for XDR complicated
      typhoid fever in children, random use of either one or both in combination is the current
      practice.

      However, keeping antibiotic stewardship in mind, it is imperative to ascertain whether
      meropenum alone is effective or should be combined with azithromycin in the treatment of this
      serious disease.

      Our study therefore compares the efficacy of monotherapy with meropenum or combination with
      azithromycin based on clinical and microbiologic remission, shortened hospital stay and less
      chances of relapse in order to then formulate a standardized protocol to treat complicated
      XDR typhoid in children thus preventing yet further antimicrobial resistance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical clearance</measure>
    <time_frame>10 days</time_frame>
    <description>improvement of the signs and symptoms as given in the operational definition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bacterial clearance</measure>
    <time_frame>5 days</time_frame>
    <description>negative blood cultures</description>
  </secondary_outcome>
  <other_outcome>
    <measure>relapse of typhoid fever</measure>
    <time_frame>15 days after completing treatment</time_frame>
    <description>reappearance of the signs and symptoms of typhoid fever along with positive blood cultures</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Typhoid Fever</condition>
  <arm_group>
    <arm_group_label>meropenum and azithromycin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>inj meropenum 20mg/kg/dose I/v in 3 divided doses and syp azithromycin 20mg/kg/day in 2 divided doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meropenum group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>inj meropenum 20mg/kg/dose I/v in 3 divided doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem Injection</intervention_name>
    <description>inj meropenum for 10 days</description>
    <arm_group_label>meropenum and azithromycin group</arm_group_label>
    <arm_group_label>meropenum group</arm_group_label>
    <other_name>meroneum</other_name>
    <other_name>penro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin Powder</intervention_name>
    <description>syp azithromycin for10days</description>
    <arm_group_label>meropenum and azithromycin group</arm_group_label>
    <other_name>azomax</other_name>
    <other_name>zetro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with extended drug resistant typhoid fever defined as culture proven typhoid fever
        caused by Salmonella Typhi or Para typhi resistant to Ampicillin, Chloramphenicol,Co
        trimoxazole,Quinolones and Ceftriaxone along with two or more of the following condition

          -  High grade fever spikes for more than three days

          -  Refusal to eat or drink

          -  Drowsy or Unconscious

          -  Convulsions

          -  Dehydration due to diarrhea or vomiting

          -  Abdominal distension with or without tenderness

          -  Bleeding diathesis like petechial rash, gum bleed, melena

          -  Jaundice or alanine transaminase more than twice of the normal range

          -  Thrombocytopenia less than fifty thousand

          -  Increase Prothrombin time and activated partial thromboplastin time

          -  Electrolyte imbalance like hyponatremia, hypernatremia, hypokalemia, hyperkalemia,
             metabolic acidosis

          -  Hypoglycemia

          -  Signs of shock like cold and mottled skin, feeble pulses, tachycardia, decreased blood
             pressure

        Exclusion Criteria:

          -  Not given informed consent

          -  Children who need ventilator or two inotrope support

          -  Severe malnutrition/immunocompromised patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>farhana zafar, mbbs,fcps</last_name>
    <role>Principal Investigator</role>
    <affiliation>ziauddin university north campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>fatima g siddiqi, mbbs,mcps</last_name>
    <phone>9+922132851880</phone>
    <phone_ext>3218</phone_ext>
    <email>fatimagsiddiqi@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>heena s rais, mbbs,fcps</last_name>
    <phone>9+922132851880</phone>
    <phone_ext>3219</phone_ext>
    <email>heena.rais@zu.edu.pk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ziauddin University</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>75600</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>July 4, 2020</last_update_submitted>
  <last_update_submitted_qc>July 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ziauddin University</investigator_affiliation>
    <investigator_full_name>Dr. Fatima G Siddiqi</investigator_full_name>
    <investigator_title>MD resident</investigator_title>
  </responsible_party>
  <keyword>XDR TYPHOID FEVER</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Typhoid Fever</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Meropenem</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

